TITLE:
Chemotherapy Related Anemia

CONDITION:
Anemia

INTERVENTION:
Darbepoetin alfa SC

SUMMARY:

      This study is investigating darbepoetin alfa for the treatment of anemia in patients with
      non-myeloid cancers who are receiving chemotherapy. Darbepoetin alfa is a recombinant
      protein that stimulates the production of red blood cells. In this study, darbepoetin alfa
      will be administered as either an injection under the skin (subcutaneously) or directly into
      a vein (intravenously).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Diagnosed with a non-myeloid malignancy

          -  Scheduled to receive a minimum of an additional 12 weeks of chemotherapy from the
             time of first dose of study drug

          -  Screening hemoglobin concentration less than or equal to 11.0g/dL

          -  ECOG performance status of 0 to 2

          -  Adequate renal and liver function

        Exclusion Criteria:

          -  History of seizure disorder

          -  Received recombinant human erythropoietin (rHuEPO) or darbepoetin alfa therapy within
             4 weeks before study day 1

          -  More than 2 red blood cell transfusions within 4 weeks before study day 1, or any red
             blood cell transfusion within 14 days before study day 1
      
